Results 51 to 60 of about 4,836 (234)
Permeation of β-Lactamase Inhibitors through the General Porins of Gram-Negative Bacteria [PDF]
, 2020 Modern medicine relies upon antibiotics, but we have arrived to the point where our inability to come up with new effective molecules against resistant pathogens, together with the declining private investment, is resulting in the number of untreatable ...
Acosta-Gutierrez S. +5 more
core +1 more source
Emerging treatment options for multi-drug-resistant bacterial infections [PDF]
, 2021 Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR ...
Andini R. +5 more
core +1 more source
Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases [PDF]
Journal of Antimicrobial Chemotherapy, 2020 Abstract Background ESBL- and carbapenemase-producing Pseudomonas aeruginosa are prevalent in, for example, the Middle East, Eastern Europe and Latin America, though rarer elsewhere. Because P. aeruginosa readily mutate to become carbapenem resistant via loss of OprD, isolates producing ESBLs are ...
Shazad Mushtaq +4 more
openaire +4 more sources
Frontiers in Microbiology, 2020 KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative.
Marina Oviaño, Eva Gato, Germán Bou
doaj +1 more source
Advances in antibiotic therapy in the critically ill [PDF]
, 2016 Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains ...
Antonelli, Massimo +13 more
core +2 more sources
Participant- and disease-related factors as independent predictors of treatment outcomes in the RESTORE-IMI 2 clinical trial: A multivariable regression analysis [PDF]
, 2023 BACKGROUND: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
Chen, Luke F +9 more
core +2 more sources
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Frontiers in Microbiology, 2019 Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now ...
Chau-Chyun Sheu +10 more
doaj +1 more source
Antibiotics, 2023 Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Maria Paz Ventero +8 more
doaj +1 more source
identifying allosteric networks to fight antibiotics resistance [PDF]
, 2018 The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza +9 more
core +1 more source
Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors
Pharmacy, 2019 Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover +2 more
doaj +1 more source